As PARP1 inhibitors are used in clinical therapy of breast, ovarian and prostate cancer, and clinical trials are ongoing to analyze their efficacy in melanoma, colorectal, pancreatic and gastric cancer [38–41], we analyzed how somatic mutations of our candidate genes are distributed among these cancers (Figure 1C). The gene discussed is PARP1; the disease is prostate cancer.